Navigation Links
Hikma CEO Interviewed on Half-Year 2011 Results

LONDON, August 25, 2011 /PRNewswire/ --

Hikma Pharmaceuticals reports lower-than-expected 3.2% increase in revenues for the first half but maintains its full-year outlook.

The international drug developer says that political unrest in the MENA region disrupted month-on-month sales in some key countries like Egypt and Tunisia.

In an interview with financial broadcaster, Hikma CEO Said Darwazah says that production is back to normal and that in spite of difficulties the group managed to grow the business organically by 3% in the MENA region.

While the group's Multi-Source Injectables division, which was acquired from Baxter Healthcare last year, was impacted by transaction delays, Mr Darwazah remains confident the business "will be breaking even" by the fourth quarter.

Hikma's CEO also makes clear that further acquisitions in emerging markets are in the pipeline.  In the interview he reiterates full-year guidance of 7% organic growth and 20% overall business growth.

The interview and transcript are available now on, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email or phone +44-(0)207-936-1372.

SOURCE Hikma Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. HIKMA - 2008 Preliminary Results Interview With CEO
2. Hikma - Half Year Results Interviews With CEO and CFO
3. Hikma Expands its Global Injectables Business - Live Webcast
4. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
5. China Sky One Medical, Inc. Interviewed in The China Perspective
6. Access Pharmaceuticals CEO Interviewed on Financial Website
7. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
8. Cord Blood America CEO Matthew Schissler Interviewed on International Successes
9. Smith & Nephew CEO Interviewed on Q2 2011 Results
10. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
11. STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
Post Your Comments:
(Date:11/24/2015)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... and chief executive officer, will present at the 27 th ... New York City . The presentation will be ... at 9:30 a.m. EST. and go ... least 15 minutes prior to the presentation to allow for ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Whitehouse Laboratories ... Laboratory. The new stand-alone facility will be strictly dedicated to basic USP 61, ... and existing clients the chance to have complete chemistry and micro testing performed by ...
(Date:11/23/2015)... with a certain type of lung nodule visible on lung ... cancer than men with similar nodules, according to a new ... the Radiological Society of North America ... Lung nodules are small masses of tissue in the lungs ... appearance on CT. Solid nodules are dense, and they obscure ...
(Date:11/23/2015)... Nov. 23, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its preliminary unaudited financial results for the second ... September 30, 2015. --> ... , Revenues for the second quarter of fiscal 2016 ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
Breaking Biology News(10 mins):